Table 5.
Representative reported results of treatment for NSCLC with ILD
| Author | year | treatment | disease | No of all pts | combined disease | No of pts. with ILD (%) | Age | median follow-up period (month) | AE (%) | Mortality after AE (%) | 3 yr. OS (%) | 5 yr. OS (%) | %FVC (or %VC) | %DLco |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chiyo | 2003 | surgery | NSCLC | 931 | ILD | 36 (3.9) | 65.5 | 43.8 | 9 (25) | 1 (11.1) | 41.5 | 35.6 | 84.9 | ― |
| Mizuno | 2012 | surgery | NSCLC | 1444 | IPF | 62 (4.3) | 71.6 | ― | 7 (13.5) | 6 (85.7) | ― | ― | %VC 95.3 | 51.1 |
| Voltolini | 2013 | surgery | NSCLC | 775 | ILD | 37 (4.8) | 69.3 | 26 | 5 (13.5) | 3 (60) | ― | 52 | 91.4 | 59.7 |
| Sato | 2014 | surgery | NSCLC | 41,742 | ILD | 1763 (4.2) | 71 | ― | 164 (9.3) | 72 (43.9) | ― | ― | %VC < 80% 263 | ― |
| 2015 | ― | 40 | %VC > 80% 1478 | ― | ||||||||||
| Omori | 2015 | surgery | NSCLC | 678 | IPF | 46 | 70.9 | 34.3 | 4 (8.7) | 3 (75) | 50.9 | 22.1 | 89.8 | 70.6 |
| Non-IPF | 57 | 70.9 | 1 (1.8) | 0 | 71.5 | 53.2 | 98.5 | 71.7 | ||||||
| Yamaguchi | 2013 | SBRT | NSCLC, MLT | 109 | subclinical ILD | 16 (14.7) | 78 | 17.1 | 2a (12.5) | 1b (50) | 48 | ― | ― | ― |
| present | 2015 | CIRT | NSCLC | 637 | ILD | 29 (4.6) | 73 | 22.8 | 2 (6.9) | 0 | 46.3 | 30.4 | 82.3 | 52.1 |
| stage I NSCLC | ― | ILD | 22 | 73 | 22.6 | 2 (9.1%) | 0 | 57.2 | 42.1 | 81.8 | 55.1 |
aGrade4–5 RP, bGrade5 RP
Abbreviations: NSCLC non-small cell lung cancer, ILD interstitial lung disease, AE acute exacerbation, IPF interstitial pulmonary fibrosis, OS overall survival rate, FVC forced vital capacity, VC vital capacity, DLco diffusion capacity of the lung, MLT metastatic lung tumor, CIRT carbon ion radiotherapy, RP radiation pneumotinis